Solid Biosciences Inc.

3.70
0.26 (7.40%)
At close: Apr 02, 2025, 3:59 PM
3.64
-1.60%
After-hours: Apr 02, 2025, 07:56 PM EDT
7.40%
Bid 3.2
Market Cap 286.72M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -3.06
PE Ratio (ttm) -1.21
Forward PE -1.14
Analyst Buy
Ask 4
Volume 1,546,164
Avg. Volume (20D) 2,486,655
Open 3.32
Previous Close 3.44
Day's Range 3.21 - 3.75
52-Week Range 2.88 - 12.95
Beta 1.98

About SLDB

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technol...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2018
Employees 100
Stock Exchange NASDAQ
Ticker Symbol SLDB
Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for SLDB stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 318.92% from the latest price.

Stock Forecasts
1 month ago
+22.08%
Solid Biosciences shares are trading higher after ... Unlock content with Pro Subscription
1 month ago
+31.51%
Solid Biosciences shares are trading higher after the company announced initial data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003.